US court ruling on access to drug safety data

The New England Journal of Medicine (29 June) discusses the implications of a recent US court ruling requiring a drug company to make safety data available to shareholders. Although the ruling doesn't relate directly to journals it's interesting in the light of current debates about publishing raw data from clinical trials.See here.